Star Combo Pharma Ltd Net Assets
Star Combo Pharma Ltd net assets. Based on the latest financial reports, Star Combo Pharma Ltd (S66) has net assets worth AU$38.68 Million AUD (≈ $27.37 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$46.99 Million ≈ $33.25 Million USD) and total liabilities (AU$8.30 Million ≈ $5.88 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Star Combo Pharma Ltd to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$38.68 Million |
| % of Total Assets | 82.33% |
| Annual Growth Rate | 28.94% |
| 5-Year Change | 5.72% |
| 10-Year Change | N/A |
| Growth Volatility | 98.2 |
Net Assets of Star Combo Pharma Ltd (2016–2025)
Net assets of Star Combo Pharma Ltd from 2016 to 2025. This chart illustrates how Star Combo Pharma Ltd's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Star Combo Pharma Ltd to measure how much of total assets are equity-financed.
Annual Net Assets for Star Combo Pharma Ltd (2016–2025)
The table below shows the annual net assets of Star Combo Pharma Ltd from 2016 to 2025. For live market cap and overall valuation, see S66 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$38.26 Million ≈ $27.07 Million |
+14.18% |
| 2024-06-30 | AU$33.51 Million ≈ $23.71 Million |
+0.76% |
| 2023-06-30 | AU$33.26 Million ≈ $23.53 Million |
-6.06% |
| 2022-06-30 | AU$35.41 Million ≈ $25.05 Million |
-2.18% |
| 2021-06-30 | AU$36.19 Million ≈ $25.61 Million |
-18.67% |
| 2020-06-30 | AU$44.50 Million ≈ $31.49 Million |
+122.50% |
| 2019-06-30 | AU$20.00 Million ≈ $14.15 Million |
+23.02% |
| 2018-06-30 | AU$16.26 Million ≈ $11.50 Million |
+3.68% |
| 2017-06-30 | AU$15.68 Million ≈ $11.10 Million |
+303.72% |
| 2016-06-30 | AU$3.88 Million ≈ $2.75 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Star Combo Pharma Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 237.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Star Combo Pharma Ltd Net Assets Breakdown (June 2025)
Star Combo Pharma Ltd net assets breakdown by equity component as of June 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$67.29 Million | 176.73% |
| Other Comprehensive Income | AU$-23.89 Million | -62.75% |
| Total Equity | AU$38.08 Million | 100.00% |
Star Combo Pharma Ltd Competitors by Market Cap
The table below lists competitors of Star Combo Pharma Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
YBM Net Inc
KQ:057030
|
$14.34 Million |
|
Moatech Co. Ltd
KQ:033200
|
$14.35 Million |
|
Pointerra Ltd
AU:3DP
|
$14.35 Million |
|
The Western India Plywoods Limited
NSE:WIPL
|
$14.35 Million |
|
Maha Rashtra Apex Corporation Limited
NSE:MAHAPEXLTD
|
$14.33 Million |
|
System1 Inc
NYSE:SST
|
$14.31 Million |
|
Cytosorbents Crp
NASDAQ:CTSO
|
$14.31 Million |
|
BBI Development S.A.
WAR:BBD
|
$14.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Star Combo Pharma Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 33,324,661 to 38,077,003, a change of 4,752,342 (14.3%).
- Net income of 5,248,658 contributed positively to equity growth.
- Dividend payments of 500,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$5.25 Million | +13.78% |
| Dividends Paid | AU$500.00K | -1.31% |
| Other Changes | AU$3.68K | +0.01% |
| Total Change | AU$- | 14.26% |
Book Value vs Market Value Analysis
This analysis compares Star Combo Pharma Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.53x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.92x to 0.53x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-06-30 | AU$0.05 | AU$0.15 | x |
| 2017-06-30 | AU$0.21 | AU$0.15 | x |
| 2018-06-30 | AU$0.26 | AU$0.15 | x |
| 2019-06-30 | AU$0.24 | AU$0.15 | x |
| 2020-06-30 | AU$0.49 | AU$0.15 | x |
| 2021-06-30 | AU$0.27 | AU$0.15 | x |
| 2022-06-30 | AU$0.26 | AU$0.15 | x |
| 2023-06-30 | AU$0.24 | AU$0.15 | x |
| 2024-06-30 | AU$0.25 | AU$0.15 | x |
| 2025-06-30 | AU$0.28 | AU$0.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Star Combo Pharma Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.78%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.87%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 1.27x
- Recent ROE (13.78%) is above the historical average (1.59%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 46.84% | 19.45% | 1.32x | 1.83x | AU$1.43 Million |
| 2017 | 10.43% | 16.71% | 0.51x | 1.23x | AU$67.05K |
| 2018 | -12.14% | -18.36% | 0.56x | 1.17x | AU$-3.60 Million |
| 2019 | -8.63% | -8.07% | 0.78x | 1.38x | AU$-3.73 Million |
| 2020 | -0.78% | -0.90% | 0.71x | 1.23x | AU$-4.80 Million |
| 2021 | -21.76% | -29.47% | 0.62x | 1.20x | AU$-11.50 Million |
| 2022 | -1.97% | -3.04% | 0.53x | 1.23x | AU$-4.24 Million |
| 2023 | -12.10% | -16.21% | 0.58x | 1.28x | AU$-7.31 Million |
| 2024 | 2.24% | 2.87% | 0.61x | 1.28x | AU$-2.59 Million |
| 2025 | 13.78% | 18.87% | 0.57x | 1.27x | AU$1.44 Million |
Industry Comparison
This section compares Star Combo Pharma Ltd's net assets metrics with peer companies in the Household & Personal Products industry.
Industry Context
- Industry: Household & Personal Products
- Average net assets among peers: $39,153,234
- Average return on equity (ROE) among peers: -56.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Star Combo Pharma Ltd (S66) | AU$38.68 Million | 46.84% | 0.21x | $14.34 Million |
| Anagenics Ltd (AN1) | $1.53 Million | -297.12% | 2.08x | $3.49 Million |
| Mcphersons Ltd (MCP) | $153.53 Million | 17.26% | 1.19x | $13.75 Million |
| Prestal Holdings Ltd (PTL) | $28.57 Million | 53.50% | 0.70x | $2.77 Million |
| Skin Elements Ltd (SKN) | $9.21 Million | -20.74% | 0.11x | $4.35 Million |
| ZOONO Group Ltd (ZNO) | $2.91 Million | -34.84% | 0.02x | $11.50 Million |
About Star Combo Pharma Ltd
Star Combo Pharma Limited manufactures and distributes health food products and nutritional supplements in Australia and China. It operates in two segments, OEM and Retail. The company develops, manufactures, markets, and sells natural health supplements and skin care products. It also provides its products through e-commerce platform to Chinese health product consumers. The company sells its pro… Read more